Professional
Added to YB: 2024-05-23
Pitch date: 2024-05-22
JAZZ [bullish]
Jazz Pharmaceuticals plc
+60.83%
current return
Author Info
No bio for this author
Company Info
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
Market Cap
$10.7B
Pitch Price
$105.41
Price Target
187.00 (+12%)
Dividend
N/A
EV/EBITDA
8.58
P/E
-29.08
EV/Sales
3.39
Sector
Pharmaceuticals
Category
growth
Jazz Pharmaceuticals plc: Xywav, Rylaze, and Epidiolex Drive Sales; Shares Undervalued
JAZZ: Q1 revenue +1% as Xywav, Epidiolex & Rylaze offset 64% Xyrem decline. FVE $187 (42% upside). Xywav, Rylaze & Epidiolex to drive double-digit growth in 2024, reaching $4.1B+ revenue. No moat rating on Xyrem patent loss. $7.2B GW acquisition weighs on returns but Epidiolex has $1B+ potential by 2025. Generic Xyrem pressure, competition from Wakix & Lumryz are risks.
Read full article (11 min)